ReviewJournal of cardiovascular translational research2017
Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 2): Clinical and Therapeutic Considerations.
Review in Journal of cardiovascular translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Impact of Diabetes Mellitus on Ventricular Structure, Arterial Stiffness, and Pulsatile Hemodynamics in Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2019Trial
- Dephospho-Uncarboxylated Matrix Gla-Protein Is Associated With Adverse Outcomes in Heart Failure.Circulation. Heart failure · 2026Article
- Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection Fraction.JACC. Heart failure · 2025Review
- Heart failure with preserved ejection fraction.Nature reviews. Disease primers · 2024Review
- Volumetric brain MRI signatures of heart failure with preserved ejection fraction in the setting of dementia.Magnetic resonance imaging · 2024Article
- Carotid wave analysis in young adults with a history of adolescent anorexia nervosa: a case control study.Journal of eating disorders · 2024Article
- A fast computational model for circulatory dynamics: effects of left ventricle-aorta coupling.Biomechanics and modeling in mechanobiology · 2023Article
- Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction.JACC. Heart failure · 2022Article
- Matrix GIa Protein, Large Artery Stiffness, and the Risk of Heart Failure With Preserved Ejection Fraction.Arteriosclerosis, thrombosis, and vascular biology · 2022Article
- Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021Review
- Association of free fatty acid binding protein with central aortic stiffness, myocardial dysfunction and preserved ejection fraction heart failure.Scientific reports · 2021Article
- Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.Scientific reports · 2021Article
- Wave Reflection at the Origin of a First-Generation Branch Artery and Target Organ Protection: The AGES-Reykjavik Study.Hypertension (Dallas, Tex. : 1979) · 2021Article
- The influence of arterial stiffness in heart failure: a clinical review.Journal of geriatric cardiology : JGC · 2021Article
- Serum Albumin Is a Marker of Myocardial Fibrosis, Adverse Pulsatile Aortic Hemodynamics, and Prognosis in Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2020Observational
- Measurement, Analysis and Interpretation of Pressure/Flow Waves in Blood Vessels.Frontiers in physiology · 2020Review
- Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2019Review
- Vitamin K Status, Warfarin Use, and Arterial Stiffness in Heart Failure.Hypertension (Dallas, Tex. : 1979) · 2019Article
- Pulsatile arterial haemodynamics in heart failure.European heart journal · 2018Review
- Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.Journal of cardiovascular translational research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Multiple phase III trials over the last few decades have failed to demonstrate a clear benefit of various pharmacologic interventions in heart failure with a preserved left ventricular (LV) ejection fraction (HFpEF). Therefore, a better understanding of its pathophysiology is important. An accompanying review describes key technical and physiologic aspects regarding the deep phenotyping of arterial hemodynamics in HFpEF. This review deals with the potential of this approach to enhance our clinical, translational, and therapeutic approach to HFpEF. Specifically, the role of arterial hemodynamics is discussed in relation to (1) the pathophysiology of left ventricular diastolic dysfunction, remodeling, and fibrosis, (2) impaired oxygen delivery to peripheral skeletal muscle, which affects peripheral oxygen extraction, (3) the frequent presence of comorbidities, such as renal failure and dementia in this population, and (4) the potential to enhance precision medicine approaches. A therapeutic approach to target arterial hemodynamic abnormalities that are prevalent in this population (particularly, with inorganic nitrate/nitrite) is also discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.